Cargando…

P16-08. Combined blockade of the PD-1 and IL-10 pathways synergistically enhance HIV-specific CD4 T cell functions

Detalles Bibliográficos
Autores principales:	Porichis, F, Kwon, DS, Tighe, DP, Pavlik, DF, Kavanagh, DG, Freeman, GJ, Walker, BD, Kaufmann, DE
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767734/ http://dx.doi.org/10.1186/1742-4690-6-S3-P237

Ejemplares similares

PD-1, IL-10, IFN-γ and IL-12 form a network to regulate HIV-1-specific CD4 T Cell and antigen-presenting cell function
por: Porichis, F, et al.
Publicado: (2012)

P16-55 LB. The role of CD4+ CD25+ regulatory T cells in the control of IL-10 mediated T cell impairment in chronic HIV Infection
por: Kwon, DS, et al.
Publicado: (2009)

EXM 92-16: 27/08/92
por: Daems, G
Publicado: (1992)

Minutes of COVAC meeting on 16.08.1985
Publicado: (1985)

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
por: Nakamoto, Nobuhiro, et al.
Publicado: (2009)

Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer
por: Dai, Congqi, et al.
Publicado: (2016)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21
por: Jones, BR, et al.
Publicado: (2009)

Comparable antiviral capacity but favorable in vitro survival of CD8s from elite controllers compared to untreated progressors
por: Shasha, D, et al.
Publicado: (2012)

08.08.08, czyli najbardziej zagadkowy dzień roku
Publicado: (2008)

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
por: Liu, Zuqiang, et al.
Publicado: (2017)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

A high-dimensional immune monitoring model of HIV-1-specific CD8 T cell responses accurately identifies subjects achieving spontaneous viral control
por: Ndhlovu, ZM, et al.
Publicado: (2012)

IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2021)

Down Regulation of c-FLIP(L) Enhance PD-1 Blockade Efficacy in B16 Melanoma
por: Wang, Yao, et al.
Publicado: (2019)

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
por: Velu, Vijayakumar, et al.
Publicado: (2008)

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
por: Felices, Martin, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
por: Guo, Fang, et al.
Publicado: (2022)

Seance de longue duree - le Vide 08.30 h., 13 juin - 08.30 h., 16 juin: Notes préliminaires
por: Munday, G L
Publicado: (1960)

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2014)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
por: Meng, Jinyu, et al.
Publicado: (2021)

P08-16 Neighborhood walkability and older people's participation in leisure activities
por: Tuomola, Essi-Mari, et al.
Publicado: (2022)

Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis
por: Jin, Kideok, et al.
Publicado: (2018)

PD08 - Measuring direct and indirect airway hyperresponsiveness in young children with obstructive symptoms
por: Kalliola, Satu, et al.
Publicado: (2014)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
por: Numata, Yasunao, et al.
Publicado: (2022)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
por: Guo, Zhiqiang, et al.
Publicado: (2017)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade
por: Miri, Seyed Mohammad, et al.
Publicado: (2022)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
por: Lee, Eun-Ji, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Blockade of IL-23: What is in the Pipeline?
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hk1mjqnp8jh7v4rh8rgs68bbk7